Prescient onboards former Array Biopharma executive
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Clinical-stage oncology company, Prescient Therapeutics Ltd (ASX:PTX), has appointed leading drug discovery and development executive, Dr James Winkler, as Vice President for business development based in the US.
Winkler brings 40 years’ experience in the international biotechnology and pharmaceutical space, with a focus on oncology and inflammation. He has overseen the discovery and advancement of multiple new drugs into clinical development, with several demonstrating mid-to-late stage clinical success.
Especially noteworthy are the senior leadership positions Winkler previously held with pioneering targeted cancer drug developer, Array BioPharma (NASDAQ:ARRY), where he established and led the company’s licensing and collaboration efforts.
US$3.1 billion Array has engaged in cancer drug collaborations with Pfizer and Merck, and in 2013 entered a multi-year licensing and collaboration partnership with Loxo Oncology (NASDAQ:LOXO) to develop a number of promising new small molecule cancer drugs.
At Array, Winkler provided leadership for multiple teams working in drug discovery, translational research and clinical development, as well as managing several collaborations with multinational pharmaceutical firms.
He also helped build an impressive pipeline of development drugs, with over 12 advancing toward Phase II or III studies.
Most recently, Winkler served as Vice President Discovery and Translational Biology with drug discovery and development company, FORMA Therapeutics, and Chief Scientific Officer with Arvinas Inc (NASDAQ:ARVN). He also worked with GlaxoSmithKline as Associate Director, Department of Oncology Research.
Winkler’s experience should be invaluable for PTX as the company advances its PTX-200 drug candidate — a novel pH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia.
PTX-200 is at various trial stages across a range of cancers, and its phase II study examining the outcomes in breast cancer patients is keenly anticipated, particularly after receiving encouraging efficacy signals in the phase 1B study with twice the expected response rate.
Prescient surges 50% as global markets tumble
PTX Managing Director and Chief Executive, Steven Yatomi-Clarke, said: “We are honoured to have such an experienced and talented leader join our team.”
“His contribution and expertise across target validation, early drug discovery, translational medicine and clinical and platform development, as well as fostering multiple industry collaborations, will help make a significant and positive difference to the growth of our business and our promising cancer therapy portfolio.”
Dr Winkler said: “Even though it is currently a small company, Prescient has unique and exciting drugs in development.”
“I am excited to join a small and passionate team and contribute to the important work of developing new treatments for people with cancer.”
This news comes less than a fortnight after PTX announced it had kicked off a collaboration agreement with a leading private US-based drug development company to develop new formulations of pH domain and Akt inhibitors. This pipeline collaboration builds on PTX’s knowledge gained during the development of PTX-200.
This development resulted in PTX’s shares surging nearly 50% from 7.2 cents to a high of 10.5 cents last week — a strong performance, given the substantial downturn in equities markets that was occurring in the background.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.